嫌色细胞
清除单元格
医学
川东北117
肾透明细胞癌
病理
免疫组织化学
嗜酸细胞瘤
肾细胞癌
小学(天文学)
TFE3型
组织微阵列
乳头状肾细胞癌
肾
细胞角蛋白
嗜酸性
转移
癌
免疫染色
染色
抗原
免疫分型
抗体
波形蛋白
肿瘤科
生物
川地34
基因表达
基因
发起人
生物化学
遗传学
干细胞
作者
Murari Lal Dhanetwal,Sonia Badwal,Gaurav Pratap Singh Gahlot,Kavita Sahai,Arvind Kumar Shukla,New Delhi India Armed Forces Medical Services
出处
期刊:Annals of Pathology and Laboratory Medicine
[Marwah Infotech]
日期:2019-11-23
卷期号:6 (11): A572-582
摘要
Background:
Tumour heterogeneity and lack of markers with high specificity makes diagnosis of renal cell carcinoma (RCC) challenging. The study was undertaken to evaluate panel of IHC markers to enable diagnosis and reproducible classification in primary and metastatic renal tumors.
Methods:
Descriptive Study wherein 100 cases of RCC and 25 trucut biopsies (20 metastatic and 5 primary renal tumors) were evaluated for morphology and immunostained by panel of immunohistochemical (IHC) markers consisting of CA-9, CD10, CK-7, AMACAR and TFE-3 with additional markers as required.
Result:
Morphologically tumors were grouped as clear cell and nonclear cell (eosinophilic and poorly differentiated). Clear cell RCCs (CCRCC), clear cell papillary RCC (CCPRCC) and multilocular cystic RCC (MCRNLMP) displayed strong statistical association of CA-9 immunostaining (p=50.00, x2-0.000). Inverse correlation was found between the intensity of the staining of CA-9 and tumor grade. (p=32.97, x2=0.000). CA-9 and CK-7 co-expression was evident in all cases of CCPRCC and MCRNLMP. Papillary RCC exhibited positive statistical correlation with CK-7 and AMACAR. E-cadherin and CD117 were required additionally to differentiate between oncocytoma and chromophobe RCC. CD10 and Pax 8 were most helpful in diagnosing metastatic RCCs
Conclusion:
IHC panel consisting of CA-9, CD10, CK7, AMACR and TFE3 helps triage RCCs with clear cell/eosinophilic cell / papillary/poorly differentiated pattern. In a setting of metastatic RCC, use of CD10 and Pax 8 together facilitate primary diagnosis of RCC when tissue available is limited.
科研通智能强力驱动
Strongly Powered by AbleSci AI